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Abstract
Summary In a 2-year randomized, placebo-controlled study
of 665 Japanese patients with primary osteoporosis, once-
yearly administration of zoledronic acid (5 mg) reduced the
risk of new morphometric vertebral fractures.
Introduction The purpose of this study was to determine the
efficacy and safety of once-yearly intravenous infusion of
ZOL in Japanese patients with primary osteoporosis.
Methods This was a two-year multicenter, randomized, place-
bo-controlled, double-blind, parallel-group comparative study
(ZONE Study). Subjects were 665 Japanese patients between
the ages of 65 and 89 years who had prevalent vertebral frac-
ture. Subjects were randomly assigned to receive once-yearly
intravenous infusion of 5 mg of ZOL or placebo at baseline
and 12 months.
Results The 2-year incidence of new morphometric vertebral
fracture was 3.0 % (10/330 subjects) in the ZOL group and
8.9 % (29/327) in the placebo group (p = 0.0016). The 24-
month cumulative incidence of new morphometric vertebral
fracture was 3.3 % in the ZOL group versus 9.7 % in the
placebo group (log-rank test: p = 0.0029; hazard ratio: 0.35;
95 % confidence interval: 0.17–0.72). The cumulative inci-
dence of any clinical fracture, clinical vertebral fracture, and
non-vertebral fracture was significantly reduced in the ZOL
group by 54, 70, and 45 %, respectively, compared to the
placebo group. At 24 months, ZOL administration increased
bone mineral density in the lumbar spine, femoral neck, and
total hip (t test: p < 0.0001). No new adverse events or
osteonecrosis of the jaw were observed in this study.
Conclusions Once-yearly administration of ZOL 5 mg to
Japanese patients with primary osteoporosis reduced the risk
of new morphometric vertebral fractures and was found to be
safe.
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Introduction
Zoledronic acid (ZOL) is a bisphosphonate that contains an
imidazole ring in a side chain, which, with once-yearly intra-
venous infusion, has been shown to cause an increase in bone
mineral density (BMD) that is mediated by a potent inhibitory
effect on bone resorption [1]. ZOL has already been approved
in a number of countries for postmenopausal osteoporosis
[2–5], glucocorticoid-induced osteoporosis [6], and male os-
teoporosis [7], and for each indication, the dosage and admin-
istration are identical (Bonce-yearly intravenous infusion of
5 mg of ZOL^).
In one large-scale clinical study, the Health Outcomes and
Reduced Incidence with Zoledronic acid Once Yearly-Pivotal
Fracture Trial (HORIZON-PFT), 7736 patients with postmen-
opausal osteoporosis received once-yearly intravenous infu-
sion of ZOL at a dose of 5 mg. After 3 years of treatment, a
significant risk reduction of vertebral fractures was observed
[5]. ZOL has also been shown to reduce the risk of hip and
non-vertebral fractures due to osteoporosis and to increase
BMD in the total hip, femoral neck, lumbar spine, and distal
radius [5, 8].
The efficacy of once-yearly intravenous infusion, however,
has not been examined in Japanese patients with primary os-
teoporosis. We conducted a 2-year placebo-controlled, ran-
domized, double-blind comparative study to determine the
fracture prevention and safety in Japanese patients with pri-
mary osteoporosis (ZOledroNate treatment in Efficacy to os-
teoporosis; ZONE study). We hypothesized that once-yearly
intravenous infusion of ZOL is effective and safe in Japanese
patients with primary osteoporosis.
Materials and methods
Study design and treatment
This was a multicenter, randomized, placebo-controlled, dou-
ble-blind, parallel-group, comparative study conducted in
Japan. All subjects were randomly assigned to either ZOL
5 mg or placebo group in a 1:1 ratio by dynamic allocation
based on the minimization method using sex and maximum
grade of prevalent vertebral fractures at enrollment as random-
ization factors. Randomized subjects were administered the
study drug once yearly by intravenous infusion (over
15 min), and after administration, efficacy and safety issues
were evaluated.
The duration of the study was 2 years. All subjects received
daily oral supplements of 610-mg calcium, 400-IU vitamin D,
and 30-mg magnesium. When acute-phase reactions (APRs)
occurred due to the administration of the study drug, investi-
gators were allowed to give the patients ibuprofen as a rescue
drug. The start of administration of study drug was postponed
if body temperature was ≥37.0 °C until it came down below
37.0 °C.
Study subjects
Subjects were ambulatory patients who had been diagnosed
with primary osteoporosis based on the Diagnostic Criteria for
Primary Osteoporosis of the Japanese Society for Bone and
Mineral Research (JSBMR) [9]; patients who have fragility
fractures caused by low BMD (young adult mean <80 %; T
score <−1.7), with between one and four vertebral fractures
from the fourth thoracic to the fourth lumbar vertebra (Th4 to
L4). Subjects were male and female Japanese patients aged
between 65 and 89 years at the time of providing informed
consent.
Key exclusion criteria were a history of bisphosphonate use
within 2 years prior to the study; serious complications includ-
ing the heart, liver, or kidney disease; creatinine clearance
<35.0 mL/min or urinary protein ≥2+; serum calcium
<8.0 mg/dL or >11.0 mg/dL; and undergoing or planning to
undergo an invasive dental procedure of the jaw bone, such as
tooth extraction, at the time informed consent was obtained.
This study was conducted in compliance with the World
Medical Association Declaration of Helsinki—Ethical
Principles for Medical Research Involving Human Subjects
and Good Clinical Practice. The protocol was reviewed by
the institutional review board at each study site. Written in-
formed consent was obtained from all subjects before enroll-
ment in the study.
Efficacy endpoints
Primary endpoint was the incidence of new morphometric
vertebral fracture. Secondary endpoints were the incidence
of clinical fracture (any clinical fractures, clinical vertebral
fractures, and non-vertebral fractures), changes from baseline
in the BMD of the lumbar spine, femoral neck, total hip, and
changes in the bone turnover markers. The incidence of oste-
oporotic fracture was also evaluated. Osteoporotic fractures
were defined as the fractures identified by radiographs at the
spine, distal forearm, humerus, ribs, clavicle/scapula/sternum,
pelvis, tibia/fibula, hip, and other femoral fractures (classified
by the World Health Organization [WHO] Scientific Group)
[10].
Efficacy measures
To assess efficacy for vertebral fractures, radiographs of the
thoracic and lumbar vertebrae were taken at baseline and at 6,
12, 18, and 24 months. An independent committee of three
experts who were blinded to treatment (TN, HK, MI) com-
pared radiographs and evaluated them based on semiquantita-
tive (SQ) methodology as well as using a quantitative method
390 Osteoporos Int (2017) 28:389–398
(QM) based on measurements of vertebral height [9]. The
incidence of vertebral fracture was defined based on methods
described by Genant et al. [11] and Wu et al. [12] as follows:
BComparison of vertebral body before and after administra-
tion reveals a change in grade, and there is a decrease of ≥20%
in either the anterior, central, or posterior vertebral height of
each vertebral body.^ Clinical fracture was defined as a frac-
ture confirmed on radiographs with clinically evident symp-
toms such as pain on the back of the trunk or in the extremi-
ties. Clinical fractures were initially identified by physicians at
each site and confirmed by radiographs or MRI.
The lumbar spine, femoral neck, and total hip BMD were
measured using dual-energy X-ray absorptiometry (DXA) at
baseline and at 6, 12, and 24 months. These were measured at
49 study sites capable of performing DXAmeasurements. All
study sites used the same DXA brand (Hologic Co., Bedford,
MA). Acceptance or rejection of the data and the need for
reanalysis were determined by the BMD Committee (MF,
HH, TS). Serum bone turnover markers were measured at
baseline and at 1, 2, 4, and 12 weeks and 6, 12, 18, and
24 months after the first infusion and at 1, 2, and 4 weeks after
the second infusion. All samples were collected under fasted
conditions. Serum was frozen, while urine was stored refrig-
erated until measurement. All samples were analyzed at a
central laboratory (LSI Medience Corporation, Tokyo,
Japan). To maintain blinding, the results of the bone turnover
marker analysis were stored centrally until the database was
locked and the study was unblinded. The bone resorption
markers measured were type I collagen cross-linked C-
telopeptide (CTx) (Elecsys β-CrossLaps/serum; with inter-
assay coefficients of variation of 1.8–6.0 %) and bone alkaline
phosphatase (BAP) (Access Ostase; 2.3–3.7 %).
Adverse events
Subjects were assessed for AEs either through self-reporting,
medical interviews, or other tests. Recorded items were the
AE name, date of onset, intervention, outcome, seriousness,
severity, and relationship with the study drug. Investigators
interviewed subjects every 3 months with a focus on AEs in
the oral cavity and whether the subject was undergoing any
dental treatment. Subjects were requested to measure their
body temperature four times a day if they felt feverish after
infusion and detail it in their self-report form. Twelve-lead
electrocardiogram tests were measured at baseline and at
1 h, 1 week, and 2 weeks after the first infusion at study sites
capable of performing measurements for QT/QTc elongation.
Statistical analyses
This study was designed to have 90 % power to detect a 50 %
reduction in the risk of newmorphometric vertebral fracture in
the ZOL group, assuming an incidence of 19 to 21 % in the
placebo group at 24 months based on data from previous
clinical trials [13, 14] and a 10 % subject discontinuation rate.
It was determined that at least 298 subjects per group were
required. All efficacy analyses were conducted on the full
analysis set (FAS). The FAS included all randomized subjects
except for those who did not have osteoporosis, did not re-
ceive the infusion, and had no available efficacy data after the
first dose of the study drug. The safety analysis set consisted
of subjects who received at least one infusion.
For the primary analysis of efficacy, the incidence of new
morphometric vertebral fracture over 24 months was analyzed
based on the Kaplan-Meier method and using log-rank tests
(two-tailed significance level of 5 %). New morphometric ver-
tebral fractures were identified by comparing radiographs taken
at baseline and at each follow-up visit. The incidence of new
morphometric vertebral facture was also presented as a hazard
ratio (HR), and the 95 % confidence interval (CI) was calculat-
ed by Cox regression analysis. The relative risk (RR) was also
calculated. Between-group analysis in the incidence of new
morphometric vertebral facture was assessed by Fisher’s exact
test. Clinical fractures were assessed by the Kaplan-Meier
method. The incidence of osteoporotic fracture was assessed
by Fisher’s exact test. Change from baseline in BMD and bone
turnover markers was compared using the t test.
For AE data, the number and percentage of subjects were
calculated based on the presence or absence of AEs in each
treatment group. Between-group analysis was performed by
Fisher’s exact test for the incidence of AEs and drug-related
AEs. The two-tailed significance level was set at 5 and 95 %
CIs that were calculated. AE occurrences were summarized
and encoded using the Medical Dictionary for Regulatory
Activities Terminology (MedDRA,MedDRA/J Version 17.1).
Results
Subjects
A total of 1311 subjects were screened at 73 study sites in
Japan (Fig. 1). Of these, 665 subjects were randomized into
two arms to receive either ZOL (n = 333) or placebo (n = 332).
Among these subjects, 542 completed the study (ZOL arm:
n = 258; placebo arm: n = 284). Analyses were performed on
661 subjects including 330 subjects (female: 309, male: 21) in
the ZOL arm and 331 subjects (female: 312, male: 19) in the
placebo arm based on the FAS (Table 1). No differences were
observed between the two arms in any of the baseline charac-
teristics in either randomized or completed population.
Fracture
The 2-year incidence of new morphometric vertebral fracture
was 3.0 % (10/330 subjects) in the ZOL group and 8.9 % (29/
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327) in the placebo group (p = 0.0016). The RR of ZOL
versus placebo was 0.34 (95 % CI: 0.17–0.69), and the rela-
tive risk reduction (RRR) was 65.8 % (the number needed to
treat: 17) (Fig. 2a). The Kaplan-Meier estimates, the primary
endpoint, were significantly lower in the ZOL group (3.3 %)
than in the placebo group (9.7 %) (p = 0.0029) (Fig. 2b). Two
or more new morphometric vertebral fractures were observed
in eight subjects in the placebo group but not observed in the
ZOL group.
In female subjects, the incidence of new morphometric
vertebral fracture was 2.9 % (9/309 subjects) in the ZOL
group and 8.8 % (27/308) in the placebo group
(p = 0.0019). The RR of ZOL versus placebo was 0.33
(95 % CI: 0.16–0.69), and the RRR was 66.8 % (Fig. 2a).
In male subjects, the incidence of new morphometric ver-
tebral fracture was 4.8 % (1/21 subjects) in the ZOL group
and 10.5 % (2/19) in the placebo group (p = 0.5962).
The cumulative incidence of any clinical fracture in the
ZOL and placebo groups was 8.2 and 17.2 % at 24 months,
respectively (p = 0.0014). The cumulative incidence of
clinical vertebral fracture in the ZOL and placebo groups
was 1.7 and 5.6 % at 24 months, respectively (p = 0.0130)
(Table 2). The cumulative incidence of non-vertebral frac-
ture in the ZOL and placebo groups was 6.9 and 12.3 % at
24 months, respectively (p = 0.0292) (Fig. 2c). The inci-
dence of the osteoporotic fracture in the ZOL and placebo
groups was 5.2 and 11.8 % at 24 months, respectively
(p = 0.0031). The number of non-vertebral osteoporotic
fractures in the ZOL and placebo groups was 2 and 3 for
hip fracture, 1 and 4 for tibia and fibula, 4 and 10 for rib,
and 7 and 6 for upper extremity, respectively.
BMD and bone turnover markers
The mean percent change from baseline in the lumbar
spine (L1–4) BMD at 6, 12, and 24 months was signif-
icantly higher in the ZOL group than that in the placebo
group at each time point (p < 0.0001) (Fig. 3a). After
24 months, the percent increase was 8.11 % in the ZOL
group. The mean percent change from baseline in fem-
oral neck BMD and total hip BMD at 6, 12, and
24 months was significantly higher in the ZOL group
than in the placebo group at each t ime point
(p < 0.001) (Fig. 3b, c). After 24 months, the percent
increase in the femoral neck and total hip BMD was
3.63 and 3.30 %, respectively (Fig. 3b, c). The propor-
tion of subjects with L1–4 BMD T score ≥−2.5 was
37.2 % at baseline and 54.2 % at 24 months in the
ZOL group.
In the ZOL group, serum CTx significantly decreased from
1 week after administration of both the first and second doses
(Fig. 3d). In the ZOL group, serum BAP gradually decreased
until 3 months after the first dose (Fig. 3e). Both markers in
the ZOL group maintained lower levels for 24 months. No
significant changes in these markers were seen in the placebo
group.
Safety
AEs occurred at a rate of 94.6 % in the ZOL group and
92.2 % in the placebo group (p = 0.2165) (Table 3). Drug-
related AEs occurred at a rate of 59.2 % in the ZOL group
and 12 % in the placebo group; the incidence was signif-
icantly higher in the ZOL group (p < 0.0001). This dif-
ference was due to the occurrence of APRs—such as py-
rexia (39.3 and 2.7 % in ZOL and placebo group, respec-
tively), arthralgia (10.8 and 0.3 %), myalgia (8.1 and
0 %), malaise (7.8 and 1.8 %), influenza-like illness (6.9
and 0 %), and headache (6.0 and 0.9 %)—in the ZOL
group within 3 days of administration. Most of these were
resolved within 3 days of onset. There were two deaths in
the ZOL group and three deaths in the placebo group. In
each case, the investigator ruled out a causal relationship
with the study drug. Serious AEs occurred at a rate of
17.4 % in the ZOL group and 13.3 % in the placebo
group. Of these serious AEs, a drug-related AE was ob-
served in one subject in the ZOL group (pneumonia) and
one subject in the placebo group (atrial fibrillation).
Elongation of QT/QTc > 500 msec was observed in one
out of 47 subjects in the ZOL group, although this had
also been observed in the subject at baseline. No tendency
toward prolongation of QT/QTc was observed in either
group. Osteonecrosis of the jaw and atypical femoral frac-
ture were not observed in this study.
Fig. 1 Patient flow. FAS full analysis set. A total of four subjects were
excluded from FAS. Three subjects in the ZOL group violated the
protocol, and one subject in the placebo group had no available efficacy
data after the first dose of the study drug
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Discussion
This study demonstrated that once-yearly administration
of ZOL significantly reduced the risk of new morpho-
metric vertebral fractures and increased BMD with a
reduction in bone turnover in Japanese patients with
primary osteoporosis. This study showed no apparent
adverse events that had not been identified in previous
clinical trials of ZOL. As the number of men included
in the study was low (6.1 %), the data mainly represent
the efficacy and safety of ZOL in postmenopausal wom-
en with osteoporosis.
Table 1 Baseline characteristics
of the study subjects Zoledronic acid (N = 330) Placebo (N = 331)
Sex
Male 21 (6.4 %) 19 (5.7 %)
Female 309 (93.6 %) 312 (94.3 %)
Age (years) 74.0 ± 5.4 74.3 ± 5.4
Height (cm) 149.79 ± 6.57 149.63 ± 5.97
Weight (kg) 52.35 ± 7.53 52.07 ± 8.23
Body mass index (kg/m2) 23.36 ± 3.22 23.26 ± 3.47
Prior usage of bisphosphonates
Never used 298 (90.3 %) 303 (91.5 %)
Used with sufficient washout 32 (9.7 %) 28 (8.5 %)
Maximum grade of prevalent vertebral fractures at baseline
0 29 (8.8 %) 35 (10.6 %)
1 54 (16.4 %) 53 (16.0 %)
2 136 (41.2 %) 144 (43.5 %)
3 111 (33.6 %) 99 (29.9 %)
Number of prevalent vertebral fractures at baseline
0 29 (8.8 %) 35 (10.6 %)
1 167 (50.6 %) 161 (48.6 %)
2 86 (26.1 %) 84 (25.4 %)
≥3 48 (14.5 %) 51 (15.4 %)
Lumbar spine T score (L1–L4)a −2.87 ± 0.84 −2.97 ± 0.83
≤−2.5 93 (62.4 %) 118 (72.0 %)
>−2.5–1.5 53 (35.6 %) 40 (24.4 %)
>−1.5 3 (2.0 %) 6 (3.7 %)
Femoral neck T scoreb −2.95 ± 0.87 −2.94 ± 0.85
≤−2.5 160 (69.6 %) 167 (71.7 %)
>−2.5–1.5 59 (25.7 %) 56 (24.0 %)
>−1.5 11 (4.8 %) 10 (4.3 %)
Total hip T scoreb −2.27 ± 0.95 −2.20 ± 0.89
≤−2.5 98 (42.6 %) 82 (35.2 %)
>−2.5–1.5 83 (36.1 %) 98 (42.1 %)
>−1.5 49 (21.3 %) 53 (22.7 %)
Lumbar spine BMD (L1–4) (g/cm2)a 0.66 ± 0.09 0.66 ± 0.09
Femoral neck BMD (g/cm2)b 0.53 ± 0.08 0.53 ± 0.08
Total hip BMD (g/cm2)b 0.65 ± 0.10 0.66 ± 0.09
25-OH Vitamin D (ng/mL) 26.17 ± 6.54 25.79 ± 6.52
Plus-minus values are expressed as mean ± standard deviation
BMD bone mineral density
a The analysis of BMD at the lumbar spine included 149 subjects in the zoledronic acid group and 164 in the
placebo group
b The analysis of BMD at the femoral neck and total hip included 230 subjects in the zoledronic acid group and
233 in the placebo group
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The efficacy of ZOL to reduce the risk of new morphomet-
ric vertebral fracture in Japanese patients with primary osteo-
porosis is similar to that seen in HORIZON-PFT. The propor-
tion of subjects with prevalent vertebral fractures at baseline
was approximately 90 % in this study, whereas it was 60 % in
HORIZON-PFT. Subjects with severe (SQ3) prevalent verte-
bral fractures were included in this study, whereas they were
excluded in HORIZON-PFT. The high incidence rate of ver-
tebral fracture in this study is due to the increased fracture
risks in the study subjects (e.g. prevalence of vertebral frac-
tures and severe deformity) [15].Mean BMD values were also
lower in this study. Another possible explanation for the high
occurrence of vertebral fractures in this study relates to the
ethnicity of the subjects. It has been reported that the risk of
vertebral fracture in Japanese postmenopausal women is
higher than that in Caucasians [16]. In HORIZON-PFT,
Asian subjects showed a higher incidence of vertebral fracture
than other ethnic groups, although the efficacy of ZOL to
reduce the risk of vertebral fracture did not differ among eth-
nic groups [17].
In this study, patients who were administered ZOL showed
significant decreases in the incidence of any clinical fractures,
clinical vertebral fractures, and non-vertebral fractures. These
data are consistent with the results obtained in HORIZON-
PFT. To our knowledge, this is the first report showing the
efficacy of a bisphosphonate to reduce the incidence of non-
vertebral fractures in Japanese subjects. The incidence of os-
teoporotic fracture as defined by WHO was also significantly
lower in the ZOL group than that in the placebo group. These
data may imply that ZOL reduces the risk of fractures, includ-
ing non-vertebral fractures, which increase the risk of subse-
quent fractures in patients with osteoporosis [18]. However,
we did not stratify between fragility and non-fragility fractures
in the collection of non-vertebral fracture data due to involv-
ing traumatic fractures, nor were these types of fractures set as
the primary endpoint; therefore, we are not able to estimate the
quantitative efficacy of ZOL in preventing non-vertebral fra-
gility fractures in Japanese patients with osteoporosis.
The mean percent change from the baseline in the lumbar
spine, total hip, and femoral neck BMD was significantly
higher in the ZOL group than that in the placebo group at all
assessment time points in this study. The values of percent
increase in lumbar spine BMD were larger than those in
HORIZON-PFT. A possible reason for the larger percent in-
creases is due to the smaller baseline BMD values in this
study. The absolute values of increased lumbar BMD from
baseline seemed to be equivalent between the two studies. In
this study, bone resorption marker (CTx) decreased rapidly
after administration of ZOL followed by a decrease in bone
formation marker (BAP). These markers maintained lower
levels in the ZOL group than in the placebo group during
the study. The changes over time in these bone turnover
markers were similar to the findings in HORIZON-PFT. The
potency of once-yearly administration of ZOL 5 mg to reduce
bone turnover and increase BMD in Japanese subjects seems
to be similar to that seen in HORIZON-PFT.
Most of the AEs found to be higher in the ZOL group are
those relating to APRs. In the ZOL group, pyrexia was report-
ed in 39.3 % of the subjects in this study, while it was reported
in 16.1 % of subjects in HORIZON-PFT [5]. Ethnic differ-
ences in the occurrence of APRs have been confirmed in
HORIZON-PFT, with respective univariate odds ratios of
Fig. 2 Incidence of fractures during the 2-year study period. a Incidence
of new morphometric vertebral fracture. Brackets indicate data for fe-
males only. Kaplan-Meier plots of incidence of b new morphometric
vertebral fracture and c non-vertebral fracture. Statistical significance
was assessed using log-rank tests, and 95 % confidence intervals (95 %
CI; lower limit, upper limit) were calculated using the Cox regression
analysis
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Fig. 3 Change over time in BMD and biochemical markers. Mean and
standard deviation plots of a the lumbar spine (L1–4) BMD, b femoral
neck BMD, c total hip BMD, d serum CTx, and e serum BAP. Statistical
significancewas assessed using the t test.BMD bonemineral density,CTx
C-telopeptide, and BAP bone alkaline phosphatase
Table 2 Effect of once-yearly
treatment with zoledronic acid on
the incidence of fractures at
24 months
Clinical fracture Zoledronic acid Placebo Log-rank test HR (95 % CI)b
n N (%)a n N (%)a
Any clinical fracture 24 330 8.2 52 331 17.2 P = 0.0014
0.46 (0.29, 0.75)
Clinical vertebral fracture 5 330 1.7 17 331 5.6 P = 0.0130
0.30 (0.11, 0.82)
Non-vertebral fracture 20 330 6.9 37 331 12.3 P = 0.0292
0.55 (0.32, 0.95)
HR hazard ratio and 95 % CI 95 % confidence interval
a Kaplan-Meier estimate
b Calculated using Cox regression analysis. Data are expressed as 95 % CIs (lower limit, upper limit)
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2.20 and 3.39 for non-Japanese Asians and Pacific Islanders
after adjustment for the other variables [19]. The high occur-
rence of pyrexia in this studymay reflect the ethnic differences
in APRs to intravenous administration of a bisphosphonate.
The APRs, including pyrexia, myalgia, and influenza-like ill-
ness, that occurred in this study mostly resolved within 3 days
of onset as has been reported before [20]. In this study, if the
subjects felt feverish after infusion, they were asked to take
their temperature four times a day. A study focusing on the
rate of pyrexia after infusion with ZOL showed that 60 % of
the subjects had a significant increase in oral temperature over
a 3-day period after infusion [20]. Therefore, it is likely that
the frequency and duration of recording body temperature
affect the incidence of pyrexia AEs after infusion with ZOL.
This study did have some limitations, including the small
sample size, the short study period, and the strict patient enroll-
ment criteria. Furthermore, a few male patients with osteoporo-
sis were enrolled in this study. However, this study demonstrated
that once-yearly administration of ZOL significantly reduced the
risk of newmorphometric vertebral fractures in postmenopausal
womenwith primary osteoporosis. Although the duration of this
study and the duration of HORIZON-PFT were only 24 and
36 months, respectively, osteonecrosis of the jaw was not ob-
served in this study and no difference in the incidence was
observed between the ZOL and placebo groups in HORIZON-
PFT (one in each group). The study was also underpowered to
test the efficacy of zoledronic acid on the prevention of hip
fracture. Based on the results of a national nutrition survey in
Japan, the dietary calcium intake of Japanese patients with pri-
mary osteoporosis was approximately 300 mg lower than the
required daily intake according to Japanese guidelines [21]. The
required daily intake of dietary calcium and vitaminD is 800mg
and 400–800 IU, respectively. Therefore, the doses of calcium
(610 mg) and vitamin D (400 IU) in this study were considered
enough to supplement the daily intake.
In conclusion, this study demonstrated the efficacy and safe-
ty of once-yearly administration of ZOL 5 mg in Japanese
patients (mainly women) with primary osteoporosis. Both the
efficacy and safety of once-yearly infusion of ZOL 5 mg in
Japanese subjects seem equivalent to those seen in the global
HORIZON-PFT study. These results suggest that ZOL may be
beneficial for the treatment of primary osteoporosis in Japan.
Table 3 Adverse events
Events All AEs
Zoledronic acid (N = 333) n (%) Placebo (N = 332) n (%)
Overall incidence of AEs
Any AE 315 (94.6) 306 (92.2)
Any serious AE 58 (17.4) 44 (13.3)
Discontinuation of the study drug 12 (3.6) 6 (1.8)
Death 2 (0.6) 3 (0.9)
AE (at least 5.0 % for any group)
Pyrexia 131 (39.3) 11 (3.3)
Nasopharyngitis 116 (34.8) 90 (27.1)
Arthralgia 54 (16.2) 24 (7.2)
Osteoarthritis 44 (13.2) 39 (11.7)
Myalgia 36 (10.8) 6 (1.8)
Eczema 31 (9.3) 24 (7.2)
Constipation 30 (9.0) 29 (8.7)
Malaise 30 (9.0) 10 (3.0)
Fall 29 (8.7) 29 (8.7)
Periarthritis 29 (8.7) 21 (6.3)
Contusion 28 (8.4) 43 (13.0)
Headache 25 (7.5) 13 (3.9)
Blood calcium decreased 24 (7.2) 2 (0.6)
Influenza-like illness 23 (6.9) 0 (0.0)
Back pain 21 (6.3) 18 (5.4)
Upper respiratory tract inflammation 21 (6.3) 18 (5.4)
Protein urine present 21 (6.3) 4 (1.2)
Dermatitis contact 18 (5.4) 16 (4.8)
Spinal osteoarthritis 17 (5.1) 14 (4.2)
AE adverse event
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